Transcend TSND201-PTSD-301

Apr 2

About the Study

For adults living with Post Traumatic Stress Disorder (PTSD)

The purpose of this study is to assess the efficacy, safety, and tolerability of TSND-201 for the treatment of PTSD symptoms compared to placebo

This study is sponsored by Transcend Therapeutics, Inc.

Eligibility

You may be eligible to participate in this study if you:

are at least 18 years of age
meet DSM-5 criteria for severe PTSD with symptom duration of at least 6 months
tried at least one pharmacological treatment for PTSD or trauma-focused psychotherapy
are free from any other clinically significant illnesses and diseases that may adversely affect participant safety or study integrity determined by the medical monitor or principal investigator.
are able to swallow and retain oral medications

If you are interested in participating in this clinical trial, please call our friendly staff at 801-871-5516 today. You can also fill out the contact form below.

View our Privacy Policy and Terms and Conditions

Condition: Schizophrenia

Jamie Robison

Transcend TSND201-PTSD-301

About the Study

Eligibility

Clinical trials advance medicine for the benefit of communities everywhere.
Inner Space Research provides patients access to emerging therapies and generates the rigorous data regulatory agencies need to evaluate their safety and efficacy.

Inner Space Research LLC

Transcend TSND201-PTSD-301

About the Study

Eligibility

Depression – Cybin 003-002

Clinical trials advance medicine for the benefit of communities everywhere.Inner Space Research provides patients access to emerging therapies and generates the rigorous data regulatory agencies need to evaluate their safety and efficacy.

Inner Space Research LLC

Clinical trials advance medicine for the benefit of communities everywhere.
Inner Space Research provides patients access to emerging therapies and generates the rigorous data regulatory agencies need to evaluate their safety and efficacy.